1
Cheuk Kun Lau, Cameron Black, Daniel Guay, Jacques Yves Gauthier, Yves LeBlanc, Patrick Roy, Yves Ducharme, Pierre Hamel: N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors. Merck Frosst Canada, Curtis C Panzer, David L Rose, June 17, 1997: US05639780 (140 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.


2
Daniel Dube, Richard Friesen, Rejean Fortin, Zhaoyin Wang, Jacques Yves Gauthier: Substituted pyridines as selective cyclooxygenase-2 inhibitors. Merck Frosst Canad, Richard C Billups, Curtis C Panzer, David L Rose, January 19, 1999: US05861419 (60 worldwide citation)

The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certa ...


3
Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien: Phenyl heterocycles as COX-2 inhibitors. Merck Frosst Canada, Curtis C Panzer, David L Rose, January 20, 1998: US05710140 (36 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.


4
Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien: Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases. Merck Frosst Canada, Curtis C Panzer, David L Rose, November 24, 1998: US05840746 (33 worldwide citation)

The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor. Although a wide range of COX-II inhibitors may be employ ...


5
Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk Kun Lau, Patrick Roy: (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors. Merck Frosst Canada, Richard C Billups, David L Rose, February 1, 2000: US06020343 (25 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.


6

7
Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier: Substituted pyridines as selective cyclooxygenase-2 inhibitors. Merck & Co, Richard C Billups, Curtis C Panzer, David L Rose, December 14, 1999: US06001843 (18 worldwide citation)

The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharma ...


8
Michael D Altman, Kenneth L Arrington, Jason Burch, Bernard Cote, Jean Francois Fournier, Jacques Yves Gauthier, Solomon Kattar, Sandra Lee Knowles, Jongwon Lim, Michelle R Machacek, Alan B Northrup, Michael H Reutershan, Joel S Robichaud, Adam J Schell, Kerrie B Spencer: Aminopyrimidines as Syk inhibitors. Merck Sharp & Dohme, Merck Canada, Eric A Meade, Valerie J Camara, May 27, 2014: US08735417 (16 worldwide citation)

The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.


9
John W Gillard, Jacques Yves Gauthier, Jillian F Evans, Rejean Fortin, Yvan Guinon, Richard A F Dixon, Douglas K Miller: 5-lipoxygenase activating protein. Merck & Co, Merck Frosst Canada, Gabriel Lopez, Joseph F DiPrima, January 26, 1993: US05182367 (14 worldwide citation)

An 18kD protein (FLAP) has been isolated from rat and human cells which is necessary for production of leukotrienes from arachidonic acid in mammalian cells containing 5-lipoxygenase. The gene (cDNA) encoding for FLAP has also been produced.


10
Robert Zamboni, Daniel Guay, Jacques Yves Gauthier: Pyridine-substituted benzyl alcohols as leukotriene antagonists. Merck Frosst Canada, Mollie M Yang, David L Rose, April 9, 1996: US05506227 (11 worldwide citation)

Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, u ...